

1 **HIV co-infection is associated with lower tuberculosis bacterial burden independent of time**
2 **to diagnosis in Botswana, a setting with widespread ART use**

3

4 **Juliana S. Chalfin^{1*}, Chelsea R. Baker^{1*}, Balladiah Kizito², Dimphe Otukile², Matsiri T.**
5 **Ogopotse², Sanghyuk S. Shin^{1**}, Chawangwa Modongo^{2**}**

6

7 ¹Sue & Bill Gross School of Nursing, University of California Irvine, Irvine, CA, USA

8 ²Victus Global Botswana Organisation, Gaborone, Botswana

9

10 *Co-first author

11 **Co-senior author

12

13 Corresponding author:

14 Sanghyuk Shin, PhD

15 Associate Professor, Sue & Bill Gross School of Nursing

16 Director, UCI Infectious Disease Science Initiative

17 University of California Irvine

18 106F Berk Hall

19 Irvine, CA 92697

20 Email: sshin2@uci.edu

21 Phone: 949-576-8675

22

23

24 **Abstract:**

25 HIV co-infection has been shown to be associated with lower tuberculosis (TB) bacterial load in
26 studies conducted prior to widespread availability of antiretroviral therapy (ART). We
27 investigated associations between HIV co-infection and TB bacterial load, accounting for
28 differences in time to TB diagnosis, in a high prevalence setting with widespread ART use. In
29 Gaborone, Botswana, 268 sputum samples from people with newly diagnosed TB were tested
30 with Xpert MTB/RIF Ultra (Xpert). TB bacterial load and time to TB diagnosis were estimated
31 using mean Xpert cycle threshold (CT) and symptom duration, respectively. Multiple linear
32 regression models and causal mediation analysis were used to determine the associations
33 between HIV and Xpert CT and assess the mediating effect of symptom duration. Mean CT
34 values were higher in people living with HIV compared to people without HIV (22.7 vs 20.3, $p <$
35 0.001). Among those living with HIV, there was a negative relationship between CD4 count and
36 mean CT value (Spearman's rho -0.20, $p = 0.06$). After controlling for gender, age, and symptom
37 duration, HIV status remained associated with CT value, with an average increase of 1.6 cycles
38 ($p = 0.009$) among people with HIV and CD4 count > 200 cells/mm³ and 2.1 cycles ($p = 0.002$)
39 in those with a CD4 count ≤ 200 cells/mm³ compared to individuals without HIV. Symptom
40 duration was also found to be associated with CT value ($p < 0.05$). We found an indirect effect of
41 HIV status on Xpert CT through the mediator, symptom duration ($\beta = 0.33$, $p = 0.048$),
42 accounting for 13.5% of the relationship. Our findings suggest that time to TB diagnosis partially
43 mediates the relationship between HIV status and CT value, but differences in pathophysiology
44 between people with and without HIV likely play a dominant role in affecting TB bacterial
45 burden.

46

47 **Introduction**

48 Globally, tuberculosis (TB) has remained a leading cause of death due to an infectious
49 disease with an estimated incidence of 10.0 million people with TB and 208,000 TB deaths
50 among people living with HIV (1). While the World Health Organization (WHO) has provided
51 goals to end the global TB epidemic, recent data indicate that targets for reduced incidence rates
52 and deaths are not being met (2). In high burden areas, HIV poses as the greatest risk factor for
53 developing TB, exacerbating existing susceptibility to primary infection or reactivation of latent
54 TB (3). Southern Africa continues to report the highest prevalence of TB/HIV co-infection,
55 demonstrating an urgent need to better understand TB transmission dynamics to reduce TB
56 incidence and mortality (4).

57 The likelihood of TB transmission depends in part on the degree of infectiousness, which
58 is often measured in clinical settings using bacterial load present in sputum (5). While this is
59 commonly done using smear microscopy, Xpert MTB/RIF assays (Xpert) have been suggested
60 as an alternative (6,7). Xpert is a diagnostic test that uses real-time polymerase chain reaction
61 (PCR). Quantitative estimation of TB bacterial load can be inferred through cycle threshold (CT)
62 values (8). CT values convey an inverse relationship to bacterial load as a higher CT value
63 signifies lower bacterial load and lower CT value signifies higher bacterial load.

64 Sputum bacterial load is influenced by pathophysiology of active TB disease, which
65 involves destruction of lung tissue, generating cavities that pass *M. tuberculosis* bacteria to
66 airways (9). Therefore, the level of lung damage contributes to the transmission potential of a
67 TB-infected individual. However, among people with HIV and TB, lower CD4+ T cell counts
68 have been associated with reduced lung inflammation (9). The reduced inflammation can result
69 in decreased cavitation, sputum bacterial load, and ultimately reduced infectiousness, as

70 suggested by the higher frequency of smear-negative pulmonary TB within untreated people
71 living with HIV (9,10). For example, a previous study has corroborated the findings that
72 increased immunosuppression, defined as CD4 count < 200 cells/mm³, was associated with
73 decreased bacterial burden, measured through CT values (6). Consequently, untreated HIV
74 infection can change TB disease presentation and reduce TB infectiousness.

75 Bacterial burden may be impacted by delays in diagnosis, as the active disease state
76 involves bacilli replication. Decreased TB bacterial burden with HIV co-infection may be
77 partially related to early TB diagnosis and treatment initiation (9,10). Treatment for HIV
78 typically involves frequent contact with the healthcare system, including increased opportunities
79 for TB case finding and prompt treatment (9). Therefore, the association between HIV status and
80 TB bacterial burden may be mediated by earlier TB diagnosis among people living with HIV.

81 Antiretroviral therapy (ART), the treatment of choice for managing HIV/AIDS, has
82 significantly improved the quality of life of people living with HIV since it decreases the viral
83 load and restores normal immune function against opportunistic pathogens (11). Access to
84 effective treatment for HIV has greatly expanded, and as of 2020 an estimated 75% of people
85 living with HIV (with known HIV status) were receiving ART (12). Further research is needed to
86 understand its effect in settings with a high burden of both HIV and tuberculosis (9). As ART
87 alters the disease process of HIV, there is a gap in knowledge of whether HIV-coinfection
88 remains associated with reduced TB infectiousness during the present time when ART is widely
89 available.

90 The purpose of this study was to determine associations between HIV co-infection and
91 sputum TB bacterial load and assess whether differences in duration of symptoms mediates this
92 association, in a high prevalence setting. This study could contribute to understanding how HIV-

93 coinfection affects infectiousness and transmission risk of TB in the current era of widespread
94 ART use.

95

96 **Methods**

97 **Study Design, Setting, and Population**

98 Botswana is a country in southern Africa with a high burden of TB and among the
99 highest rates of TB-HIV co-infection in the world. This cross-sectional analysis is part of an
100 ongoing population-based TB transmission study in Gaborone, the capital city of Botswana.
101 Participants were sequentially enrolled after diagnosis of TB from community or health care
102 facilities. All participants were recruited in accordance with Botswana national guidelines.
103 Active case finding, involving the screening of all patients, and passive case finding, involving
104 clinical diagnosis of patients presenting with TB symptoms, were utilized in 26 public health
105 facilities. Participants included male and female patients of all ages. Clinical and demographic
106 data were collected through a standardized questionnaire that captured information about TB
107 symptoms and their duration (< 1 month, 1-2 months, 2-3 months, and > 3 months prior to
108 diagnosis). Smoking and alcohol use were collected as these variables are known to impact TB
109 transmission as well as the immune system. Smoking has been shown to increase infectiousness
110 by increasing the aerosolization of bacilli through changes in mucus and increased cough
111 frequency (13). Furthermore, alcohol impairs the immune system leading to increased
112 susceptibility to TB as well as reactivation and is associated with social environments that
113 facilitate TB transmission (14). Participants provided their consent for us to access their medical
114 records to collect TB and HIV history, including CD4 cell counts, viral load, and ART history.
115 We recorded CT values for five probes in the Xpert (Xpert MTB/RIF Ultra) test used for clinical

116 diagnosis. Mean CT values across all probes was used as the primary measure of bacterial load.

117 Participant-reported duration of symptoms was used as an approximate measure of time to

118 diagnosis.

119 **Statistical Analysis**

120 Standard descriptive statistics were used to characterize the data. The sample population

121 of CT values was compared between groups of participants by HIV status and CD4 count using

122 the nonparametric Wilcoxon test. CT values were also compared between groups of participants

123 by symptom duration using the Wilcoxon test to determine significant difference. Odds ratios

124 were estimated using a dichotomous variable for symptom duration (< 1 month and ≥ 1 month)

125 by HIV status and CD4 count category. Spearman correlation was used to assess the relationship

126 between CD4 counts and mean CT values among participants living with HIV since values were

127 not normally distributed. Bivariate linear regression was used to examine the association

128 between mean CT value as the outcome variable and selected patient characteristics as predictor

129 variables. Multivariate linear regression models were used to control for confounding variables

130 including age and gender to examine the relationship with HIV status as the primary exposure

131 variable of interest. We also compared multivariate models with and without symptom duration

132 to estimate the extent to which the association between HIV status and bacterial load is explained

133 by differences in time to diagnosis. Causal mediation analysis was performed using the R

134 package mediation to determine the mediation effects of symptom duration, as a dichotomous

135 variable, on the relationship between HIV status and CT value (15). Bootstrapping was used to

136 test the significance of the indirect effect, using 500 samples. All statistical analyses were

137 conducted using the R statistical software version 4.1.2 (16).

138 **Ethics Approval**

139 This study was approved by institutional review boards at the University of Irvine,
140 California and Botswana Ministry of Health and Wellness Human Research Development
141 Committee. All participants provided written consent for research use of clinical data.

142

143 Results

144 Sample Population

145 During January 2021 to August 2022, 379 participants had positive Xpert results, of
146 which 338 participants had valid corresponding Xpert CT value results. Of those, 70 individuals
147 (20.7%) were excluded from analysis due to missing HIV results (n=12), CD4 counts that were
148 either missing (n=42) or taken greater than six months from the initial interview (n=13), or
149 missing symptom duration (n=3). A total of 268 participants were included in our analysis.
150 Overall, 68.7% were male, and the median age was 34 (interquartile range [IQR]: 25-45.25)
151 (Table 1). People with HIV comprised 33.2% with a CD4 count median of 263 cells/mm³ (IQR:
152 100-523). At the time of enrollment, 25% and 43.3% reported smoking and alcohol use,
153 respectively. The proportion of participants reporting TB symptoms for < 1 month was 55.1%
154 and 38.5% among people with and without HIV, respectively. Among individuals with HIV,
155 43.8% had CD4 counts of ≤ 200 cells/mm³, 61.8% reported taking ART at the time of TB
156 diagnosis, and median viral load was 30.0 copies/mL (IQR: ≤ 20 -400; Figure 1).

Table 1: Demographic and Clinical Information by HIV Status of Individuals in Botswana 2021-2022

	Negative (N=179)	Positive (N=89)	Overall (N=268)
Gender			
Female	57 (31.8%)	27 (30.3%)	84 (31.3%)
Male	122 (68.2%)	62 (69.7%)	184 (68.7%)
Age			
0-19	18 (10.1%)	0 (0%)	18 (6.7%)
20-29	72 (40.2%)	10 (11.2%)	82 (30.6%)

30-39	42 (23.5%)	29 (32.6%)	71 (26.5%)
40-49	19 (10.6%)	28 (31.5%)	47 (17.5%)
50-65	17 (9.5%)	22 (24.7%)	39 (14.6%)
65+	11 (6.1%)	0 (0%)	11 (4.1%)
Currently Smoking			
Yes	44 (24.6%)	23 (25.8%)	67 (25.0%)
No	135 (75.4%)	66 (74.2%)	201 (75.0%)
Currently Drinking Alcohol			
Yes	78 (43.6%)	38 (42.7%)	116 (43.3%)
No	101 (56.4%)	51 (57.3%)	152 (56.7%)
Symptom Duration			
<1 month	69 (38.5%)	49 (55.1%)	118 (44.0%)
1-2 months	70 (39.1%)	27 (30.3%)	97 (36.2%)
2-3 months	16 (8.9%)	9 (10.1%)	25 (9.3%)
3+ months	24 (13.4%)	4 (4.5%)	28 (10.4%)
HIV Status			
HIV-	179 (100%)	0 (0%)	179 (66.8%)
HIV+ CD4 > 200	0 (0%)	50 (56.2%)	50 (18.7%)
HIV+ CD4 ≤ 200	0 (0%)	39 (43.8%)	39 (14.6%)

157

158 **Figure 1:** (A) Histogram of individuals' mean CT values among all participants. (B) Histogram
 159 of individuals' CD4 counts among participants living with HIV. (C) Histogram of individuals'
 160 viral load among participants living with HIV. (D) Bar graph of frequency, measured in percent,
 161 of ART history among participants living with HIV.

162 Symptom Duration

163 The percentage of participants experiencing symptoms >1 month was 61.5% among
 164 people without HIV, 48% among those with HIV and CD4 counts > 200 cells/mm³, and 41%
 165 among those with HIV and CD4 counts ≤ 200 cells/mm³ (Figure 2). Participants living with HIV
 166 with CD4 counts ≤ 200 cells/mm³ had significantly decreased odds of symptom duration >1
 167 month compared to those without HIV (OR 0.44, p = 0.021), but no statistically significant
 168 difference was found between people with HIV and CD4 count >200 cells/m³ and people
 169 without HIV (Table 2).

170 **Figure 2:** Comparison of symptom duration length between HIV status.

Table 2. Odds ratio for Symptom Duration Greater than 1 Month by HIV Status and CD4 Count Breakdown

Characteristic	OR ¹	95% CI ¹	p-value
HIV status			
HIV-	—	—	
HIV+ CD4 > 200	0.58	0.31, 1.09	0.090
HIV+ CD4 ≤ 200	0.44	0.21, 0.88	0.021

¹OR = Odds Ratio, CI = Confidence Interval

171

172 **Distribution of CT Value**

173 The mean CT value across all participants was 21.1 (IQR: 18.1-23.1) with a range of
174 17.1-33.9 (Figure 1A). Mean CT values were higher among people living with HIV in
175 comparison to people without HIV (22.7 vs 20.3, $p < 0.001$) (Figure 3A). This was noted for
176 those with CD4 >200 cells/mm³ ($p = 0.009$) as well as ≤ 200 cells/mm³ ($p < 0.001$). However,
177 the difference between participants in the two CD4 count categories was not significant (23.0 vs
178 23.3 for CD4 >200 cells/mm³ and ≤ 200 cells/mm³, respectively, $p = 0.34$).

179 **Figure 3:** (A) Boxplot comparing mean CT values between HIV status and CD4 count, among
180 those living with HIV. (B) Boxplot comparing mean CT values between groups of symptoms
181 duration prior to diagnosis, measured in months. (C) Scatterplot comparing mean CT values and
182 CD4 cell counts among participants with HIV.

183 Among participants living with HIV, there was a weak negative correlation between CD4
184 count and mean CT value (Spearman's rho -0.2; $p = 0.06$; Figure 3C). Participants who reported
185 symptoms for < 1 month had higher mean CT values compared to those that reported symptoms
186 for 1-2 months, 2-3 months, and > 3 months prior to diagnosis ($p = 0.013$; $p = 0.013$; $p = 0.017$
187 respectively) (Figure 3B).

188 **Individual Level Predictors of CT Value**

189 In a bivariate linear regression model, compared to participants without HIV, mean CT
 190 values were increased by 2.1 ($p < 0.001$) in participants living with HIV with CD4 counts >200
 191 cells/mm³ and by an average of 2.7 ($p < 0.001$) in participants living with HIV with CD4 counts
 192 ≤ 200 cells/mm³ (Table 3). The bivariate linear regression model displays a decreasing trend in
 193 mean CT values as the duration of symptoms increases.

194 **Table 3. Bivariate Linear Regression Model for Mean CT Value among All**
 195 **Participants**

Characteristic	N	Beta	95% CI ¹	p-value	In a
Gender	268				
Female		—	—		
Male		-0.43	-1.4, 0.59	0.41	
Age	268	0.06	0.03, 0.09	<0.001	
Currently Smoking	268				
Yes		—	—		
No		0.86	-0.23, 2.0	0.12	
Currently Drinking Alcohol	268				
Yes		—	—		
No		0.36	-0.59, 1.3	0.46	
Symptom Duration	268				
<1 month		—	—		
1-2 months		-1.5	-2.5, -0.42	0.006	
2-3 months		-2.6	-4.2, -0.92	0.002	
3+ months		-2.4	-4.0, -0.81	0.003	
HIV Status	268				
HIV-		—	—		
HIV+ CD4 > 200		2.1	0.89, 3.3	<0.001	
HIV+ CD4 ≤ 200		2.7	1.3, 4.0	<0.001	
CD4 Count	89	0.00	-0.01, 0.00	0.11	
Viral Load	77	0.00	0.00, 0.00	0.57	
ART History	85				
Patient has never taken ARTs		—	—		
Patient is taking ARTs		-0.42	-2.5, 1.7	0.70	
Patient took ARTs but stopped		-3.7	-7.4, -0.02	0.049	

¹CI = Confidence Interval

196 multivariate linear regression model, HIV status, including the CD4 count breakdown for
 197 participants with HIV, and symptom duration were significant predictors of mean CT (Table 4).
 198 When controlling for gender, age, and symptom duration, the mean CT value was 1.6 cycles

199 higher ($p = 0.009$) among people with HIV and CD4 count > 200 cells/mm³ and 2.1 cycles
 200 higher ($p = 0.002$) in those with a CD4 count ≤ 200 cells/mm³ compared with the reference group
 201 of individuals without HIV. After controlling for gender, age, and HIV status, the mean CT value
 202 decreased by 1.1 cycles ($p = 0.026$), 2.2 cycles ($p = 0.007$), and 1.6 cycles ($p = 0.043$) for
 203 participants that reported TB symptoms 1-2 months, 2-3 months, and > 3 months, respectively,
 204 prior to diagnosis compared to those that reported symptoms < 1 month prior. The mean CT
 205 value also increased by 0.04 cycles with age as a continuous variable ($p = 0.022$) in the
 206 multivariate linear regression model controlling for gender, HIV status, and symptom duration.
 207 In a multivariate linear regression model that only included people with HIV, the association
 208 between CD4 count and CT did not reach statistical significance when controlling for gender,
 209 age, CD4 count, viral load, and ART History ($p = 0.2$; Table 5).

Table 4. Multivariate Regression Models for Mean CT among All Participants

Characteristic	Excluding Symptom Duration			Including Symptom Duration		
	Beta	95% CI ¹	p-value	Beta	95% CI ¹	p-value
Gender						
Female	—	—		—	—	
Male	-0.70	-1.7, 0.28	0.2	-0.69	-1.7, 0.29	0.2
Age	0.04	0.01, 0.08	0.007	0.04	0.01, 0.07	0.022
HIV Status						
HIV-	—	—		—	—	
HIV+ CD4 > 200	1.7	0.53, 2.9	0.005	1.6	0.40, 2.8	0.009
HIV+ CD4 ≤ 200	2.3	1.0, 3.6	<0.001	2.1	0.78, 3.4	0.002
Symptom Duration						
<1 month				—	—	
1-2 months				-1.1	-2.2, -0.14	0.026
2-3 months				-2.2	-3.8, -0.62	0.007

210	3+ months	-1.6	-3.2, -0.05	0.043
-----	-----------	------	-------------	-------

211 ¹CI = Confidence Interval

Table 5. Multivariate Regression Model for Mean CT among Participants Living with HIV

Characteristic	Beta	95% CI ¹	p-value
Gender			
Female	—	—	
Male	-0.44	-2.8, 1.9	0.7
Age	0.02	-0.09, 0.13	0.7
CD4 Count by 10	-0.03	-0.07, 0.02	0.2
Log10 Viral Load	0.31	-0.76, 1.4	0.6
ART History			
Patient has never taken ARTs	—	—	
Patient is taking ARTs	-0.03	-2.8, 2.7	>0.9
Patient took ARTs but stopped	-3.7	-8.0, 0.54	0.086

¹CI = Confidence Interval

212
 213 The mediation analysis found a total effect of HIV status of CT value of $\beta = 2.3$ ($p <$
 214 0.001 ; Table 6). The indirect effect through the mediator, symptom duration, was statistically
 215 significant ($\beta = 0.33$, $p = 0.048$) with mediation accounting for 13.5% of the relationship. The
 216 direct effect of HIV status on Xpert CT remained statistically significant ($\beta = 2.1$, $p < 0.001$).

Table 6: Mediation Analysis of the association between HIV status and mean Xpert CT values with symptom duration as mediator among people newly diagnosed with tuberculosis in Botswana

	Estimate	p-value
Indirect Effect	0.326	0.048
Direct Effect	2.085	<0.001
Total Effect	2.411	<0.001
Prop. Mediated	0.135	0.048

217
 218 **Discussion**

219 Using mean CT as a measure of TB bacterial burden, we found an association between
 220 decreased sputum bacterial burden and increased immunosuppression among people living with
 221 HIV in a high burden setting during the time of widespread access to ART. Additionally,

222 increase in duration of symptoms was associated with decrease in mean CT values, indicating an
223 increase in sputum bacterial burden. Our findings are consistent with earlier findings that those
224 living with HIV experience lower TB sputum bacterial burden compared to those without HIV
225 (6, 8). For example, Burger et al. compared CT values from sputum and saliva from both people
226 living with and without HIV, and concluded that patients living with HIV had significantly lower
227 bacterial load than individuals without HIV (17). However, prior studies did not investigate the
228 mediating role of time to TB diagnosis. Our study findings support the observation that HIV
229 changes the presentation of TB with a lower sputum TB bacterial load, potentially due to less
230 inflammation and cavitation (6, 8).

231 As ART decreases the viral load and restores normal immune function, it has the
232 potential to shift the TB disease presentation to be similar to those without HIV. A study using
233 smear microscopy found that ART increased smear positivity and cavitation among participants
234 with HIV, with lower proportions compared to individuals without HIV (18). As ART has a
235 positive relationship with CD4 count, we expected higher CD4 counts among people with HIV
236 in our study and similar levels of TB bacterial load by HIV status. However, our data show a
237 significant proportion of people with HIV/TB co-infection have advanced immune suppression
238 and, therefore, TB bacterial load remains lower among people living with HIV compared to
239 those without HIV even in settings with widespread ART use.

240 Symptom duration prior to diagnosis can be used as a measure of diagnostic delay. Our
241 data suggests a negative correlation between symptom duration and CT values after controlling
242 for confounding variables. Previous studies suggest that people living with HIV are more likely
243 to be diagnosed for TB faster due to more severe symptoms or increased contact with healthcare
244 systems (9). Our data supports this finding since a significant difference was found between

245 participants with and without HIV with symptom duration for < 1 month before diagnosis. Our
246 findings suggest that the association between HIV-associated immunosuppression and CT values
247 is partially mediated by differences in timeliness of TB diagnosis between people with and
248 without HIV. However, 86.5% of this association was not mediated by TB symptom duration,
249 which suggests that differences in pathophysiology between people with and without HIV play a
250 dominant role in affecting TB bacterial burden.

251 Limitations to our study include the cross-sectional design, which limits our ability to
252 establish causal relationships. Predictors of CT values are important to understand since the level
253 of bacterial load has implications for transmission. Future studies should examine HIV status in
254 relation to TB transmission among close contacts to directly demonstrate the applicability of CT
255 values in determining transmission risks.

256 In conclusion, our data demonstrate that HIV status remains a predictor of TB
257 infectiousness even when ART is widely available. Duration of symptoms was found to partially
258 mediate this relationship. Individuals living without HIV may be at a greater risk of transmitting
259 TB to their contacts. Further research should directly assess TB outcomes and transmission based
260 on CT results to advance understanding of its utility in clinical and community health practice.

261

262

263

264

265

266

267 **Acknowledgements**

268 We are grateful to the study participants who donated their time and clinical specimens to make
269 this study possible.

270


271 **References**

- 272 1. World Health Organization. Global Tuberculosis Report 2021. [cited 2023 Jan 10]. Available
273 from: [https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-](https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021)
274 [tuberculosis-report-2021](https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021)
- 275 2. World Health Organization. Tuberculosis (TB) [Internet]. [cited 2022 Jan 10]. Available
276 from: <https://www.who.int/news-room/fact-sheets/detail/tuberculosis>
- 277 3. Bruchfeld J, Correia-Neves M, Källenius G. Tuberculosis and HIV Coinfection. Cold Spring
278 Harb Perspect Med. 2015 Jul 1;5(7):a017871.
- 279 4. Akwafuo SE, Abah T, Oppong JR. Evaluation of the Burden and Intervention Strategies of
280 TB-HIV Co-Infection in West Africa. J Infect Dis Epidemiol. 2020 Jul 10. 6:143.
281 doi.org/10.23937/2474-3658/1510143
- 282 5. Dye C, Williams BG. The Population Dynamics and Control of Tuberculosis. Science. 2010
283 May 14;328(5980):856–61.
- 284 6. Hanrahan CF, Theron G, Bassett J, Dheda K, Scott L, Stevens W, et al. Xpert MTB/RIF as a
285 Measure of Sputum Bacillary Burden. Variation by HIV Status and Immunosuppression. Am
286 J Respir Crit Care Med. 2014 Jun;189(11):1426–34.
- 287 7. Beynon F, Theron G, Respeito D, Mambuque E, Saavedra B, Bulo H, et al. Correlation of
288 Xpert MTB/RIF with measures to assess Mycobacterium tuberculosis bacillary burden in
289 high HIV burden areas of Southern Africa. Sci Rep. 2018 Mar 26;8(1):5201.


- 290 8. Lawn SD, Nicol MP. Xpert® MTB/RIF assay: development, evaluation and implementation
291 of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. *Future*
292 *Microbiol.* 2011 Sep;6(9):1067–82.
- 293 9. Peters JS, Andrews JR, Hatherill M, Hermans S, Martinez L, Schurr E, et al. Advances in the
294 understanding of Mycobacterium tuberculosis transmission in HIV-endemic settings. *Lancet*
295 *Infect Dis.* 2019 Mar 1;19(3):e65–76.
- 296 10. Kwan CK, Ernst JD. HIV and Tuberculosis: a Deadly Human Syndemic. *Clin Microbiol*
297 *Rev.* 2011 Apr;24(2):351–76.
- 298 11. Treatment [Internet]. 2021 [cited 2023 Jan 10]. Available from:
299 <https://www.cdc.gov/hiv/basics/livingwithhiv/treatment.html>
- 300 12. UNAIDS data 2020 [Internet]. [cited 2022 Mar 27]. Available from:
301 <https://www.unaids.org/en/resources/documents/2020/unaid-data>
- 302 13. Turner RD, Bothamley GH. Smoking and the Transmission of Tuberculosis. *Pediatr Infect*
303 *Dis J.* 2015 Oct;34(10):1138.
- 304 14. Imtiaz S, Shield KD, Roerecke M, Samokhvalov AV, Lönnroth K, Rehm J. Alcohol
305 consumption as a risk factor for tuberculosis: meta-analyses and burden of disease. *Eur*
306 *Respir J.* 2017 Jul;50(1):1700216.
- 307 15. Tingley D, Yamamoto T, Hirose K, Keele L, Imai K. mediation: R Package for Causal
308 Mediation Analysis. *J Stat Softw* [Internet]. 2014 [cited 2022 Dec 13];59(5). Available from:
309 <http://www.jstatsoft.org/v59/i05/>
- 310 16. R Core Team. R: A language and environment for statistical computing; 2018.

- 311 17. Burger ZC, Aung ST, Aung HT, Rodwell T, Seifert M. 658. Effect of HIV Status on
312 Tuberculosis Load as Detected by Xpert MTB/RIF in Sputum vs. Saliva Samples. Open
313 Forum Infect Dis. 2020 Oct 1;7(Supplement_1):S385–6.
- 314 18. Munthali L, Khan PY, Mwaungulu NJ, Chilongo F, Floyd S, Kayange M, et al. The effect of
315 HIV and antiretroviral therapy on characteristics of pulmonary tuberculosis in northern
316 Malawi: a cross-sectional study. BMC Infect Dis. 2014 Feb 25;14(1):107.


Distribution of CT Values




Distribution of CD4 Counts




Distribution of Viral Load




ART History Frequency




Percent with symptoms > 1 month by HIV status



Boxplot of CT Values by HIV Category



Boxplot of CT Values by Symptom Duration



Scatterplot of CT Values vs CD4 Cell Counts

